Seeking Alpha4dAutomated tone · bearish
Merck's experimental eye drug meets goal in trial, but raises safety concernsInvesting.com5dAutomated tone · neutral
Merck’s remigromig meets non-inferiority goal in DME trialSeeking Alpha8dAutomated tone · neutral
Halozyme wins Dutch patent ruling against Merck’s Keytruda SCSeeking Alpha17dAutomated tone · neutral
Merck signs up to $2.13B license deal with SciBrunchSeeking Alpha20dAutomated tone · neutral
Merck pulls BLA for antibody-drug conjugate I-DXd for small cell lung cancerSeeking Alpha21dAutomated tone · neutral
Merck’s diabetic macular edema therapy succeeds in Phase 2b/3 trialSeeking Alpha23dAutomated tone · bullish
Merck says FDA approved label update for PAH therapy WinrevairSeeking Alpha24dAutomated tone · bullish
Merck secures Japanese approval for subcutaneous KeytrudaYahoo Finance33dAutomated tone · neutral
Jim Cramer Explains Why Merck (MRK) Is His Fantasy Defense StockSeeking Alpha37dAutomated tone · bullish
Inhibrx cancer therapy outperforms Merck’s Keytruda in mid-stage trialCoinDesk37dAutomated tone · neutral
Tracking cocoa may be just the beginning for PwC, Merck, Hashgraph provenance systemYahoo Finance46dAutomated tone · neutral
Jim Cramer Called Moderna Inc. (NASDAQ:MRNA) & Merck’s Trial Results EncouragingYahoo Finance46dAutomated tone · bullish
Is Merck Stock Outperforming the Nasdaq?Yahoo Finance46dAutomated tone · neutral
Healthcare’s Best Week Since June Traces Back to a Single Moderna and Merck Cancer TrialInvesting.com48dAutomated tone · bullish
Success after a century of failures: Inside Moderna and Merck’s cancer vaccine breakthroughYahoo Finance48dAutomated tone · neutral
Moderna (MRNA) & Merck (MRK): What’s Happening With These Two Stocks?Seeking Alpha50dAutomated tone · bearish
GSK’s shingles shot cuts cardiovascular risk compared with Merck’s ZostavaxYahoo Finance51dAutomated tone · bullish
Merck (MRK) Surges on a Melanoma Win. Can Intismeran Extend Keytruda’s Growth Runway?Seeking Alpha53dAutomated tone · neutral
Notable healthcare headlines for the week: Moderna, Merck, and Twist Bioscience in focusSeeking Alpha54dAutomated tone · neutral
Notable analyst calls this week: Apple, Merck and Analog Devices among top picksInvesting.com55dAutomated tone · neutral
Merck stock analysis: great pipeline at a stretched valuationInvesting.com55dAutomated tone · bullish
Why is Merck stock surging to a 52-week high today?Investing.com55dAutomated tone · bullish
Merck stock hits all-time high at 153.53 USDSeeking Alpha56dAutomated tone · bearish
Merck upgraded at Morgan Stanley after cancer trial win; RBC downgradesSeeking Alpha56dAutomated tone · neutral
Congo to receive 70K doses of Merck Ebola vaccineCNBC56dAutomated tone · bullish
Jim Cramer's top 10 things to watch in the stock market ThursdayYahoo Finance56dAutomated tone · neutral
Here Are Thursday’s Top Wall Street Analyst Research Calls: Alphabet, Analog Devices, Crown Castle, Ebay, EPR Properties, Etsy, Merck & Co., Shopify, TJX Companies, and MoreSeeking Alpha57dAutomated tone · bullish
Biotechs hit a post-pandemic high after mRNA trial win for Moderna, MerckMarketWatch57dAutomated tone · bullish
Moderna’s experimental vaccine prevents cancer recurrence, in ‘historic’ win for personalized medicine. Its stock soared.Seeking Alpha57dAutomated tone · bullish
Moderna, Merck rise after late-stage trial win for mRNA cancer therapyInvesting.com57dAutomated tone · bullish
Why is Merck stock surging today?CNBC57dAutomated tone · bullish
Cancer vaccine from Moderna, Merck shows promise in late-stage trial; both stocks soarSeeking Alpha60dAutomated tone · neutral
Notable healthcare headlines for the week: Eli Lilly, Hims & Hers Health, and Merck in focusInvesting.com61dAutomated tone · neutral
Merck EVP DeLuca sells $5.9m in stockInvesting.com69dAutomated tone · neutral
Merck EVP David Maraldo sells $2.4 million of common stockSeeking Alpha70dAutomated tone · neutral
Merck KGaA GAAP EPS of €2.16, revenue of €5.4BYahoo Finance70dAutomated tone · neutral
After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?Yahoo Finance70dAutomated tone · bullish
Why This Biotech Dealmaker — Tied To Merck, Travere — Charged HigherSeeking Alpha72dAutomated tone · neutral
Merck projects 2026 EPS of $2.66-$2.76 as it raises revenue view to $66.3B-$67.3B following Terns dealSeeking Alpha72dAutomated tone · bullish
Merck in charts: Keytruda remains the growth engine in Q2 as Gardasil reboundsYahoo Finance72dAutomated tone · neutral
Merck posts better-than-expected second-quarter results on Keytruda strengthCNBC72dAutomated tone · neutral
Merck hikes revenue outlook as new drug sales grow, but cuts profit guidance due to deal chargesYahoo Finance72dAutomated tone · neutral
The Merck Product That Absolutely Demolished Wall Street's ForecastsInvesting.com73dAutomated tone · neutral
Merck earnings ahead: Can new launches offset margin squeeze?Seeking Alpha76dAutomated tone · neutral
Dividend Roundup: Wells Fargo, Merck, Citigroup, Carnival Corp, and moreSeeking Alpha77dAutomated tone · neutral
BMS granted FDA review for label expansion of Merck-partnered anemia therapySeeking Alpha78dAutomated tone · neutral
Merck declares $0.85 dividendInvesting.com80dAutomated tone · bullish
Merck stock hits 52-week high at $131.84